• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.

作者信息

Levy Corinne, Werner Andreas, Rybak Alexis, Béchet Stéphane, Batard Christophe, Hassid Frédéric, Desandes Roxane, Frandji Bruno, Ouldali Naim, Cohen Robert

机构信息

ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France.

AFPA, Association Française de Pédiatrie Ambulatoire, Ancenis, France.

出版信息

J Pediatric Infect Dis Soc. 2024 Jul 20;13(7):371-373. doi: 10.1093/jpids/piae051.

DOI:10.1093/jpids/piae051
PMID:38779958
Abstract
摘要

相似文献

1
Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.尼塞维单抗对门诊全因性细支气管炎的早期影响：法国一项前瞻性多中心监测研究
J Pediatric Infect Dis Soc. 2024 Jul 20;13(7):371-373. doi: 10.1093/jpids/piae051.
2
Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.2023 年 9 月至 2024 年 1 月期间法国儿科重症监护病房住院的呼吸道合胞病毒毛细支气管炎病例中尼赛利珠单抗的有效性。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13311. doi: 10.1111/irv.13311.
3
Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care.单克隆抗体尼塞韦林进行普遍免疫接种对减轻需要儿科重症监护的严重细支气管炎负担的影响。
Eur J Pediatr. 2024 Sep;183(9):3897-3904. doi: 10.1007/s00431-024-05634-z. Epub 2024 Jun 23.
4
Nirsevimab and Hospitalization for RSV Bronchiolitis.尼赛珠单抗与 RSV 毛细支气管炎住院治疗。
N Engl J Med. 2024 Jul 11;391(2):144-154. doi: 10.1056/NEJMoa2314885.
5
Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.父母在接受 nirsevimab 免疫计划前对呼吸道合胞病毒的了解：西班牙一个自治区的免疫态度。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357439. doi: 10.1080/21645515.2024.2357439. Epub 2024 Jun 10.
6
Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).尼氏司他单抗免疫预防在医院和初级保健环境中对呼吸道合胞病毒相关结局的有效性：加泰罗尼亚（西班牙）婴儿的回顾性队列研究。
Arch Dis Child. 2024 Aug 16;109(9):736-741. doi: 10.1136/archdischild-2024-327153.
7
Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.尼赛珠单抗和双联母体疫苗对婴儿 RSV 细支气管炎的潜在影响：基于人群的建模研究。
J Infect Public Health. 2024 Aug;17(8):102492. doi: 10.1016/j.jiph.2024.102492. Epub 2024 Jul 8.
8
Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study.在儿科门诊护理中，nirsevimab治疗呼吸道合胞病毒细支气管炎的有效性：一项检测阴性病例对照研究。
Lancet Reg Health Eur. 2024 Jul 23;44:101007. doi: 10.1016/j.lanepe.2024.101007. eCollection 2024 Sep.
9
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).尼氏司他单抗预防儿童呼吸道合胞病毒病。西班牙儿科传染病学会（SEIP）声明。
An Pediatr (Engl Ed). 2023 Oct;99(4):257-263. doi: 10.1016/j.anpede.2023.09.006. Epub 2023 Sep 22.
10
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.

引用本文的文献

1
Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis.尼塞韦单抗、呼吸道合胞病毒（RSV）母体疫苗和老年人RSV疫苗在现实世界中的应用：一项系统评价和荟萃分析。
EClinicalMedicine. 2025 Jun 3;84:103281. doi: 10.1016/j.eclinm.2025.103281. eCollection 2025 Jun.
2
Respiratory syncytial virus preventives for children in Australia: current landscape and future directions.澳大利亚儿童呼吸道合胞病毒预防措施：现状与未来方向
Med J Aust. 2025 Jun 16;222(11):579-586. doi: 10.5694/mja2.52671. Epub 2025 May 25.
3
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus.
尼塞韦单抗对呼吸道合胞病毒的估计有效性
JAMA Netw Open. 2025 Mar 3;8(3):e250380. doi: 10.1001/jamanetworkopen.2025.0380.
4
Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection.借鉴已成功实施单克隆抗体预防措施以预防呼吸道合胞病毒（RSV）感染的国家的国际建议和经验。
Ital J Pediatr. 2025 Feb 4;51(1):26. doi: 10.1186/s13052-025-01844-9.
5
Changes in Respiratory Syncytial Virus-Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France.法国里昂引入尼塞韦单抗后呼吸道合胞病毒相关住院病例流行病学的变化
Influenza Other Respir Viruses. 2024 Dec;18(12):e70054. doi: 10.1111/irv.70054.
6
Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study.尼塞韦单抗对住院婴儿呼吸道合胞病毒细支气管炎的影响：一项真实世界研究
Pediatr Infect Dis J. 2025 Apr 1;44(4):e124-e126. doi: 10.1097/INF.0000000000004630. Epub 2024 Nov 26.
7
Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study.尼塞韦单抗对呼吸道合胞病毒的真实世界有效性：一项检测阴性病例对照研究。
medRxiv. 2024 Sep 12:2024.09.12.24313545. doi: 10.1101/2024.09.12.24313545.